The role of HIV-DNA testing in clinical practice

New Microbiologica

Volumn 33, Issue 1, 2010, Pages 1-11

  D'Ettorre, Gabriella ^a   Zaffiri, Lorenzo ^a   Ceccarelli, Giancarlo ^a   Mastroianni, Claudio M ^a   Vullo, Vincenzo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

HTV DNA; Reservoirs; Viral marker

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIAGNOSTIC AGENT; VIRUS DNA;

ANIMAL; ARTICLE; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; VIROLOGY; VIRUS LOAD;

ANIMALS; ANTI-HIV AGENTS; DNA, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77950223662     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. ALCAMÍ J., LAIN DE LERA T., FOLGUEKA L., PEDRAZA M.A., JACQUÉ J.M., BACHELERIE F., NORIEGA A.R., HAY R.T., HARRICH D., GAYNOR R.B., VIREUZIER J.L., ARENZANA-SEISDEDOS F. (1995). Absolute dependence on kappa B responsive elements for initiation and Tat-mediated amplification of HIV transcription in blood CD4 T lymphocytes. EMBO J. 14 (7), 1552-1560.
2. BELL P., MONTANER L.J., MAUL G.G. (2001). Accumulation and intranuclear distribution of unintegrated human immunodeficiency virus type 1 DNA. J. Virol. 75 (16), 7683-7691.
3. BLANKSON J.N., FINZI D., PIERSON T.C., SABUNDAYO B.P., CHADWICK K., MARGOLICK J.B., QUINN T.C., SILICIANO R.F. (2000). Biphasic decay of latendy infected CD4+ T cells in acute human immunodeficiency virus type 1 infection J. Infect. Dis. 182 (6), 1636-1642.
4. BON I, ALESSANDRINI F., BORDERI M., GORINI R., RE M.C. (2007). Analysis of HIV-I drug-resistant variants in plasma and peripheral blood mononuclear cells from untreated individuals: implications for clinical management. New Microbiol. 30 (3), 313-317.
5. BROOKS D.G., KITCHEN S.G., KTTCHEN C.M., SCRIPTUREADAMS D.D., ZACK J.A. (2001). Generation of HIV latency during thymopoiesis. Nat. Med. 7 (4): 459464.
6. BRUSSEL A., DELEUS O., SONIGO P. (2005). Alu-LTR real-time nested PCR assay for quantifying integrated HIV-I DNA. Methods Mol. Biol. 304, 139-154.
7. BUKRINSKY M.I., STANWICK T.L., DEMPSEY M.P., STEVENSON M. QUIESCENT T. (1991). Lymphocytes as an inducible virus reservoir in HIV-I infection. Science. 254, 423-427
8. BURTON C.T., NELSON M.R., HAY P., GAZZARD B.G., GOTCH F.M., IMAMI N. (2005). Immunological and virological consequences of patient-directed antiretroviral therapy interruption during chronic HIV-I infection. Clin. Exp. Immunol. 142 (2), 354-361.
9. BUTLER S.L., HANSEN M.S., BUSHMAN F.D. (2001). A quantitative assay for HIV DNA integration in vivo. Nat Med. 7(5), 631-634.
10. CHEN B.K., FEINBERG M.B., BALTIMORE D. (1997). The kappaB sites in the human immunodeficiency virus type 1 long terminal repeat enhance virus replication yet are not absolutely required for viral growth. J. Virol. 71 (7) 5495-5504.
11. CHUN T.W., ENGEL D., BERREY M.M., SHEA T., COREY L., FAUCI A.S. (1998). Early establishment of a pool of latendy infected, resting CD4(+) T cells during primary HIV-I infection. Proc. Natl. Acad. Sci. USA. 95 (15), 8869-8873.
12. CHUN T.W., NICKLE D.C., JUSTEMENT J.S., LARGE D., SEMERJIAN A., CURLIN M.E., O'SHEA M.A., HALLAHAN C.W., DAUCHER M., WARD DJ., MOIR S., MULLINS J.I., KOVACS C., FAUCI A.S. (2005). HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J. Clin. Invest. 115 (11), 3250-3255.
13. CHUN T.W., STUYVER L., MIZELL S.B., EHLER L.A., MICAN J.A., BASELER M., LLOYD A.L., NOWAK M.A., FAUCI A.S. (1997). Presence of an inducible HIV-I latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94 (24), 13193-13197.
14. COSSARIZZA A., POCCIA E, AGRATI C., D'OFFIZI G., BUGARINI R., PlNTI M., BORGHI V., MUSSINI C., Esposrro R., IPPOLTTO G., NARCISO P. (2004). Highly active anti-retroviral therapy restores CD4+ Vbeta T-cell repertoire in patients with primary acute HIV infection but not in treatment-naive HIV+ patients with severe chronic infection. J. Acquir. Immune Defic. Syndr. 35, 213-222.
15. DEEKS S.G., WRIN T., LIEGLER T., HOH R., HAYDEN M., BARBOUR J.D., HELLMANN N.S., PETROPOULOS C.J., McCUNE J.M., HELLERSTEIN M.K., GRANT R.M. (2001). Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viraemia. N. Engl. J. Med. 344 (7), 472-480.
16. D'ETTORRE G., ZAFFIRI L., CECCARELLI G., ANDREOTTT M., MASSETTI A.P., VELLA S., MASTROIANNI C.M., VULLO V. (2007). Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up. HIV Clin. Trials. 8 (3): 182-188.
17. DHHS PANEL ON ANTIRETROVIRAL GUIDELINES FOR ADULT AND ADOLESCENTS. (2009). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 1-128.
18. DORNADULA G., NUNNARI G., VANELLA M., ROMAN J., BABINCHAK T., DE SIMONE J., STERN J., BRAFFMAN M., ZHANG H., POMERANTZ RJ. (2001). Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups. J. Infect. Dis. 183 (11), 1682-1687.
19. DORNADULA G., ZHANG H., VANUITERT B., STERN J., LIVORNESE L. JR, INGERMAN M.J., WITEK J., KEDANIS R.J., NATKIN J., DE SIMONE J., POMERANTZ R.J. (1999). Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA. 282 (17), 1627-1632.
20. FINZI D., BLANKSON J., SILICIANO J.D., MARGOUCK J.B., CHADWICK K., PIERSON T., SMITH K., LISZIEWICZ J., LORI F., FLEXNER C., QUINN T.C., CHAISSON R.E., ROSENBERG E., WALKER B., GANGE S., GALLANT J., SILICIANO R.F. (1999). Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5 (5), 512-517.
21. FINZI D., HERMANKOVA M., PIERSON T., CARRUTH L.M., BUCK C., CHAISSON R.E., QUINN T.C., CHADWICK K., MARGOLICK J., BROOKMEYER R., GALLANT J., MARKOWITZ M., HO D.D., RICHMANN D.D., SILICIANO R.F. (1997). Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 278, 1295-1300.
22. GARRIGUE I., PELLEGRIN I., HOEN B., DUMON B., HARZIC M., SCHRIVE M.H., SERENI D., FLEURY H. (2000). Cell-associated HIV-1-DNA quantitation after highly active antiretroviral therapy-treated primary infection in patients with persistently undetectable plasma HIV-1 RNA. AIDS. 14 (18), 2851-2855.
23. GHOSN J., PELLEGRIN I., GOUJARD C., DEVEAU C., VIARD J.P., GALIMAND J., HARZIC M., TAMALET C., MEYER L., ROUZIOUX C., CHADC M.L. (2006). HIV-1 resistant strains acquired at the time of primary infection massively fuel The cellular reservoir and persist for lengthy periods of time. AIDS. 20 (2), 159-170.
24. GILLIM-ROSS L., CARA A., KLOTMAN M.E. (2005). HIV-1 extrachromosomal 2-LTR circular DNA is longlived in human macrophages. Viral. Immunol. 18 (1), 190-196.
25. GOMEZ C., HOPE T.J. (2005). The ins and outs of HIV replication. Cell. Microbiol. 7 (5), 621-626.
26. GOUJARD C., BONAREK M., MEYER L., BONNET F., CHAIX M.L., DEVEAU C., SINET M., GALIMAND J., DELFRAISSY J.F., VENET A., ROUZIOUX C., MORLAT P. (2006). CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin. Infect. Dis. 42 (5), 709-715.
27. + T cells and odier viral reservoirs during chronic infection: insights from treatment and treatment-interruption trials. Curr. Opin. HIV AIDS. 1, 62-68.
28. HATZAKIS A.E., TOULOUMI G., PANTAZIS N., ANASTASSAPOULOU C.G., KATSAROU O., KARAFOULIDOU A., GOEDERT J.J., KOSTRHCIS L.G. (2004). Cellular HIV-1 DNA load predicts HIV-RNA rebound and The outcome of highly active antiretroviral therapy. AIDS. 18 (17), 2261-2267.
29. HAVLIR D.V., BASSETT R., LEVTIAN D., GILBERT P., TEBAS P., COLLIER A.C., HIRSCH M.S., IGNACIO C., CONDRA J., GÜNTHARD H.E, RICHMAN D.D., WONG J.K. (2001). Prevalence and predictive value of intermittent viraemia with combination HIV therapy. JAMA. 286 (2), 171-179.
30. HAVLIR D.V., KOELSCH K.K., STRAIN M.C., MARGOT N., Lu B., IGNACIO C.C., MILLER M.D., WONG J.K. (2005). Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. J. Infect. Dis. 191 (7), 1164-1168.
31. JONES L.E., PERELSON A.S. (2007). Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 45 (5), 483-493.
32. KOSTRIKIS L.G., TOULOUMI G., KARANICOLAS R., PANTAZIS N., ANASTASSOPOULOU C., KARAFOULIDOU A., GOEDERT JJ., HATZAKIS A. (2002). Quantitation of human immunodeficiency virus type 1 DNA forms with The second template switch in peripheral blood cells predicts disease progression independentiy of plasma RNA load. J. Virol 76 (20), 10099-10108.
33. LANGFORD D., MARQUTE-BECK J., DE ALMEIDA S., LAZZARETTO D., LETENDRE S., GRANT I., MCCUTCHAN J.A., MASLIAH E., ELLIS R.J. (2006). Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients. J. Neuro Virol. 12, 100-108.
34. LEWIN S.R., MURRAY J.M., SOLOMON A., WIGHTMAN F., CAMERON P.U., PURCELL D.J., ZAUNDERS J.J., GREY P., BLOCH M., SMITH D., COOPER D.A., KELLEHER A.D. (2008). Virologie determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infection. J. Acquir. Immune Defic. Syndr. 47 (2), 140-147.
35. MCDERMOTT J.L., MARTINI I., FERRARI D., BERTOLOTTI F., GIACOMAZZI C., MURDACA G., PUPPO E, lNDIVERI F., VARNIER O.E. (2005). Decay of human immunodeficiency virus type 1 unintegrated DNA containing two long terminal repeats in infected individuals after 3 to 8 years of sustained control of viremia. J. Clin. Microbiol. 43 (10), 5272-5274.
36. MELLORS JW, MARGOLICK JB, PHAIR JP, RINNOLDO CR, DETELS R, JACOBSON LP, MUNOZ A. (2007). Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 Cell count slope for progression to AIDS and death in untreated HIV-1 infection. JAMA. 297 (21), 2349-2350.
37. MIRA J.A., MACÍAS J., NOGALES C., FERNÁNDEZ-RIVERA J., GARCÍA-GARCÍA J.A., RAMOS A., PINEDA J.A. (2002). Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunological failure. Antivir. Ther. 7 (4), 251-256.
38. MOCROFT A., DEVEREUX H., KINLOCH-DE-LOES S., WILSON D., MADGE S., YOULE M., TYRER M., LOVEDAY C., PHILLIPS A.N., JOHNSON M.A. (2000). Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine. AIDS. 14 (11), 1545-1552.
39. MOCROFT A., LEDERGERBER B., KATLAMA C., KIRK O., REISS P., D'ARMINIO MONFORTE A., KNYSZ B., DIETRICH M., PHILLIPS A.N., LUNDGREN J.D. (2003). Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 362, 22-29.
40. NABEL G., BALTIMORE D. (1987). An inducible transcription factor activates expression of human immmunodeficiency virus in T cells. Nature. 326 (6114), 711-713.
41. O'DOHERTY U., SWIGGARD W.J., JEYAKUMAR D., MCGAIN D., MALIM M.H. (2002). A sensitive, quantitative assay for human immunodeficiency virus type 1 integratioa J. Virol. 76 (21), 10942-10950.
42. PALELLA F.J. JR, DELANEY K.M., MOORMAN A.C., LOVELESS M.O., FUHRER J., SATTEN G.A., ASCHMAN D.S., HOLMBERG S.D. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl J. Med. 338 (13), 853-860.
43. PALMISANO L., GIULIANO M., CHJAROTTI F., ZANCHETTA M., ANDREOTTI M., PIRILLO M.E, RIVA E., ANTONELLI G., DE ROSSI A., VELLA S. (2008). Modification of HIV1 DNA and provirus infected cells during 24 months of intermittent Highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 48 (1), 68-71.
44. PAOLUCCI S., BALDANTI E, CAMPANINI G., ZAVATTONI M., CATTANEO E., DOSSENA L., GERNA G. (2001). Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naive and HAART patients. J. Med. Virol. 65 (2), 207-217.
45. PAUZA C.D., TRIVEDI P., MCKECHNIE T.S., RICHMAN D.D., GRAZIANO EM. (1994). 2-LTR circular viral DNA as a marker for human immunodeficiency virus type 1 infection in vivo. Virology. 205 (2), 470-478.
46. PELLEGRIN L., CAUMONT A., GARRIGUE I., MEREL P., SCHRIVE M.H., FLEURY H., DUPON M., PELLEGRIN J.L., RAGNAUD J.M. (2003). Predictive value of provirus load and DNA human immunodeficiency virus genotype for successful abacavir-based simplified therapy. J. Infect. Dis. 187 (1), 38-46.
47. PERSAUD D., PIERSON T., RUFF C., FINZI D., CHADWICK K.R., MARGOUCK J.B., RUFF A., HUTTON N., RAY S., SILLICIANO R.F. (2000). A stable latent reservoir for HIV-I in resting CD4(+) T lymphocytes in infected children. J. Clin. Invest. 105 (7), 995-1003.
48. PIERSON T., MCARTHUR J., SILICIANO R.F. (2000). Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu. Rev. Immunol 18, 665-708.
49. POMERANTZ R.J. (2003). Reservoirs, sanctuaries, and residual disease: the hiding spots of HIV-1. HIV Clin. Trials. 4 (2), 137-143.
50. RAMRATNAM B., MITTLER J.E., ZHANG L., BODEN D., HURLEY A., FANG E, MACKEN C.A., PERELSON A.S., MARKOWITZ M., HO D.D. (2000). The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat. Med. 6 (1), 82-85.
51. RAMRATNAM B., RIBEIRO R., HE T., CHUNG C., SIMON V., VANDERHOEVEN J., HURLEY A., ZHANG L., PERELSON A.S., Ho D.D., MARKOWITZ M. (2004). Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J. Acquir. Immune Defic. Syndr. 35 (1), 33-37.
52. RE M.C., VITONE E, BON I., SCHJAVONE P., GIBELLINI D. (2006). Meaning of DNA detection during the follow-up of HIV-1 infected patients: a brief review. New Microbiol. 29 (2), 81-88.
53. ROBINSON H.L., ZINKUS D.M. (1990). Accumulation of human immunodeficiency virus type 1 DNA in T cells: results of multiple infection events. J. Virol 64 (10), 4836-4841.
54. ROSENBERG E.S., ALTFELD M., POON S.H., PHILLIPS M.N., WILKES B.M., ELDRIDGE R.L., ROBBINS G.K., D'AQUILA R., GOULDER R.J., WALKER B.D. (2000). Immune control of HIV-1 after early treatment of acute infection. Nature. 407, 523-526.
55. ROUZIOU C., HUBERT J.B., BURGARD M., DEVEAU C., GOUJARD C., BARY M., SERENI D., VIARD J.P., DELFRAISSY J.F., MEYER L. (2005). Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J. Infect. Dis. 192 (1), 46-55.
56. RUFF C. T., RAY S. C., KWON P., ZINN R., PENDLETON A., HUTTON N., ASHWORTH R., GANGE S., QUINN T.C., SILICIANO R.F., PERSAUD D. (2002). Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in paediatric patients with extensive antiretroviral exposure. J. Virol 76 (18), 9481-9492.
57. SARMATI L., ANDREONI C., NICASTRI E., TOMMASI C., BUONOMINI A., DTLTTORRE G., CORPOLONGO A., DORI L., MONTANO M., VOLPI A., NARCISO P., VULLO V., ANDREONI M. (2009). Prognostic factors of longterm CD4+count guided interruption of antiretroviral treatment. J. Med. Virol 81 (3), 481-487.
58. SEDAGHAT A.R., DINOSO J.B., SHEN L., WILKE C. O., SILICIANO R.F. (2008). Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc. Natl Acad. Sci. USA. 105 (12), 4832-4837.
59. SHARKEY M.E., TEO I., GREENOUGH T., SHAROVA N., LUZURJAGA K., SULLIVAN J.L., BUCY R.P., KOSTRIKIS L.G., HAASE A., VERYARD C., DAVARO R.E., CHEESEMAN S.H., DALY J.S., BOVA C., ELLISON R.T. 3RD, MADY B., LAI K.K., MOYLE G., NELSON M., GAZZARD B., SHAUNAK S., STEVENSON M. (2000). Persistence of episomal HIV-1 infection intermiates in patients on highly active anti-retroviral therapy. Nat. Med. 6, 76-81.
60. SHEN L., SILICIANO R.F. (2008). Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J. Allergy. Clin. Immunol 122 (1), 22-28.
61. SHIRAMIZU B., PAUL R., WILLIAMS A., SHIKUMA C., WAITERS M., GROVE J., VALCOUR V. (2007). HIV proviral DNA associated with decreased neuropsychological function. J Neuropsychiatry Clin Neurosci. 19 (2), 157-163.
62. SHJRAMIZU B., WILLIAMS A.E., SHIKUMA C., VALCOUR V. (2009). Amount of HIV-DNA in peripheral blood mononuclear cells is proportional to the severity of HIV1 associated neurocognitive disorders. J. Neuropsychiatry Clin. Neurosci. 21 (1), 68-74.
63. SILICIANO J.D., KAJDAS J., FINZI D., QUINN T.C., CHADWICK K., MARGOUCK J.B., KOVACS C., GANGE S.J., SILICIANO R.F. (2003). Long-term follow-up studies confirm die stability of die latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 9 (6), 727-728.
64. SILVA W.P., SANTOS D.E., LEAL E., BRUNSTEIN A., SUCUPIRA M.C., SABINO E.C., DIAZ R.S. (2006). Reactivation of ancestral strains of HIV-1 in the gp l20 V3 env region in patients failing antiretroviral therapy and subjected to structured treatment interruption. Virology. 354 (1), 35-47.
65. STEVENSON M., HAGGERTY S., LAMONICA C., MEIER C.M., WELCH S.K., WASIAK A.J. (1990). Integration is not necessary for expression of human immunodeficiency virus type 1 protein products. J. Virol. 64, 2421-2425.
66. STEVENSON M., STANWICK T., DEMPSEY M.P., LACONIC C.A. (1990). HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J. 9, 1551-1560.
67. STRAIN M.C., GÜNTHARD H.E, HAVLIR D.V., IGNACIO C.C., SMITH D.M., LEIGH-BROWN A.J., MACARANAS T.R., LAM R.Y., DALY O.A., FISCHER M., OPRAVIL M., LEVINE H., BACHELER L., SPINA CA., RICHMAN D.D., WONG J.K. (2003). Heterogeneous clearance rates of longlived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc. Natl. Acad. SCi. USA. 100 (8), 4819-4824.
68. STRAIN M.C., LITTLE S.J., DAAR E.S., HAVLIR D.V., GUNTHARD H.E, LAM R.Y., DALY O.A., NGUYEN J., IGNACIO C.C., SPINA CA., RICHMAN D.D., WONG J.K. (2005). Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV1. J. Infect. Dis. 191 (9), 1410-1418.
69. SWIGGARD WJ., BAYTOP C., YU J.J., DAI J., LI C., SCHRETZENMAIR R., THEODOSOPOULOS T., O'DOHERTY U. (2005). Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. J. Virol. 79 (22), 14179-14188.
70. TEO L., VERYARD C., BARNES H., AN S.F., JONES M., LANTOS P.L., LUTHERT P., SHAUNAK S. (1997). Circular forms of unintegrated human immunodeficiency virus type 1 DNA and high levels of viral protein expression: association with dementia andmultinucleated giant cells in the brains of patients with AIDS. J Virol 71 (4), 2928-2933.
71. VANDERGRAAFFN., KUMAR R., BURRELL C.J., LI P. (2001). Kinetics of human immunodeficiency virus type 1 (HIV) DNA integration in acutely infected cells as determined using a novel assay for detection of integrated HiV DNA. J. Virol 75, 11253-11260.
72. VIARD J.P., BURGARD M., HUBERT J.B., AARON L., RABIAN C., PERTUISET N., LOURENÇO M., ROTHSCHILD C., ROUZIOUX C (2004). Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-I DNA level. AIDS. 18 (1), 45-49.
73. WONG J.K., HEZAREH M., GONTHARD H.E, HAVUR D.V., IGNACIO C.C., SPINA C.A., RICHMAN D.D. (1997). Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 278 (5341), 1291-1295.
74. Wu Y. (2004). HIV-I gene expression: lessons from provirus and non-integrated DNA. Retrovirology. 1-13.
75. ZHANG L., RAMRATNAM B., TENNER-RACZ K., HE Y., VESANEN M., LEWIN S., TALAL A., RACZ P., PERELSON A.S., KORBER B.T., MARKOWITZ M., Ho D.D. (1999). Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N. Engl. J. Med. 340 (21), 1605-1613.